4.8 Article

Acellular cardiac scaffolds enriched with MSC-derived extracellular vesicles limit ventricular remodelling and exert local and systemic immunomodulation in a myocardial infarction porcine model

Journal

THERANOSTICS
Volume 12, Issue 10, Pages 4656-4670

Publisher

IVYSPRING INT PUBL
DOI: 10.7150/thno.72289

Keywords

extracellular vesicles; cardiac fibrosis; ventricular remodeling; mesenchymal stromal; stem cells; myocardial infarction; swine; pig model; immunomodulation

Funding

  1. Fundacio La Marato de TV3 [201516-10]
  2. MICINN [PID-2019-110137RB-I00, SAF2017-84324-C2-1-R]
  3. Instituto de Salud Carlos III [PI18/00256, ICI19/00039, ICI20/00135, RD16/0011/0006, CB16/11/00403, PI21/01703]
  4. AGAUR Generalitat de Catalunya [2017-SGR-483, 2017-SGR-301]
  5. Societat Catalana de Cardiologia
  6. Institut Catala de Salut
  7. Red RICORS [PI21/01703]
  8. ISCIII-Subdireccion General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER)

Ask authors/readers for more resources

This study demonstrates the preclinical efficacy of locally delivering cATMSC-EV in an acute myocardial infarction (MI) pig model, showing improved cardiac function and reduced myocardial remodeling.
Rationale: Extracellular vesicles (EVs) from mesenchymal stromal cell (MSC) are a potential therapy for cardiac healing after myocardial infarction (MI). Nevertheless, neither their efficient administration nor therapeutic mechanisms are fully elucidated. Here, we evaluate the preclinical efficacy of a tissue engineering approach to locally deliver porcine cardiac adipose tissue MSC-EV (cATMSC-EV) in an acute MI pig model. Methods: After MI by permanent ligation of the coronary artery, pigs (n = 24) were randomized to Untreated or treated groups with a decellularised pericardial scaffold filled with peptide hydrogel and cATMSC-EV purified by size exclusion chromatography (EV-Treated group) or buffer (Control group), placed over the post-infarcted myocardium. Results: After 30 days, cardiac MRI showed an improved cardiac function in EV-Treated animals, with significantly higher right ventricle ejection fraction (+20.8% in EV-Treated; p = 0.026), and less ventricle dilatation, indicating less myocardial remodelling. Scar size was reduced, with less fibrosis in the distal myocardium (-42.6% Col I in EV-Treated vs Untreated; p = 0.03), a 2-fold increase in vascular density (EV-Treated; p = 0.019) and less CCL2 transcription in the infarct core. EV-treated animals had less macrophage infiltration in the infarct core (-31.7% of CD163(+)cells/field in EV-Treated; p = 0.026), but 5.8 times more expressing anti-inflammatory CD73 (p = 0.015). Systemically, locally delivered cATMSC-EV also triggered a systemic effect, doubling the circulating IL-1ra (p = 0.01), and reducing the PBMC rush 2d post-MI, the TNF alpha and GM-CSF levels at 30d post-MI, and modulating the CD73(+) and CCR2(+) monocyte populations, related to immunomodulation and fibrosis modulation. Conclusions: These results highlight the potential of cATMSC-EV in modulating hallmarks of ischemic injury for cardiac repair after MI.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available